10x Genomics, Inc. is raising its full year 2023 revenue guidance and now expects revenue in the range of $610 million to $625 million, representing 18% to 21% growth over full year 2022. This compares to previous expectation of $600 million to $620 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.83 USD | -0.72% | -7.93% | -55.63% |
15/05 | Transcript : 10x Genomics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 04:20 PM | |
07/05 | Bruker's NanoString Secures Patent Case Win in Germany | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-55.63% | 2.97B | |
-6.26% | 12.23B | |
-3.86% | 8.17B | |
+5.88% | 5.78B | |
+33.66% | 5.74B | |
-7.35% | 4.24B | |
+13.62% | 2.73B | |
-4.16% | 2.38B | |
+30.67% | 2.26B | |
-4.31% | 1.87B |
- Stock Market
- Equities
- TXG Stock
- News 10x Genomics, Inc.
- 10X Genomics, Inc. Raises Revenue Guidance for Full Year 2023